B&L Sees Visudyne Coverage Loss As Envision Gain; Market Rebound In Sight
This article was originally published in The Gray Sheet
Executive Summary
Bausch & Lomb views CMS' decision not to cover QLT's Visudyne for age-related macular degeneration in patients with occult lesions as a net positive for the company, which is developing a treatment of its own